TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Breast Cancer
Interventions
DRUG

Carboplatin and a Taxane

"All patients will receive Carboplatin and a Taxane for 4 cycles.~* Patients who achieve a complete radiological response will proceed directly to surgery.~* Patients without a complete radiological response will receive Doxorubicin and Cyclophosphamide, with or without Pembrolizumab, for an additional 4 cycles before surgery."

Trial Locations (5)

Unknown

Instituto D'Or de Pesquisa e Ensino de Brasília, Brasília

Instituto D'Or de Pesquisa e Ensino de Curitiba, Curitiba

Instituto D'Or de Pesquisa e Ensino do Rio de Janeiro, Rio de Janeiro

Instituto D'Or de Pesquisa e Ensino de Salvador, Salvador

Instituto D'Or de Pesquisa e Ensino de São Paulo, São Paulo

All Listed Sponsors
collaborator

Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)

UNKNOWN

lead

D'Or Institute for Research and Education

OTHER